SCHEMBL20764341

SCHEMBL20764341

Cc1ccccc1NC(=O)c1ccc(-c2cccc(O)c2)s1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESRRG P62508 9/20 0.68
ESR1 P03372 5/20 0.68
ESR2 Q92731 2/20 0.68
HPGDS O60760 4/20 0.58
TP53 P04637 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
MAPK11 Q15759 1/20 0.55
MAPK14 Q16539 1/20 0.55
RXFP1 Q9HBX9 2/20 0.55
MAPT P10636 1/20 0.55
HSD17B1 P14061 2/20 0.55
NPC1 O15118 1/20 0.53
PPARG P37231 1/20 0.53
RAB9A P51151 1/20 0.53
NCOA2 Q15596 1/20 0.53
NCOA1 Q15788 1/20 0.53
NCOA3 Q9Y6Q9 1/20 0.53
HSD17B2 P37059 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26727122 0.88 ESRRG (0.72) ESRRGESR1ESR2TP53SMN1; SMN2
SCHEMBL20764029 0.85 TP53 (0.81) ESRRGESR1ESR2HPGDSTP53
SCHEMBL26727114 0.84 ESRRG (0.76) ESRRGESR1ESR2TP53SMN1; SMN2
SCHEMBL31337398 0.82 NPC1 (0.81) ESRRGESR1ESR2HPGDSTP53
SCHEMBL20764233 0.81 ESRRG (1.00) ESRRGESR1ESR2HPGDSTP53
SCHEMBL26727117 0.80 ESRRG (0.60) ESRRGESR1ESR2TP53SMN1; SMN2
SCHEMBL1752474 0.80 MAPK11 (0.85) MAPK11MAPK14
SCHEMBL28202710 0.80 SMN1; SMN2 (0.54) ESRRGESR1ESR2TP53SMN1; SMN2
SCHEMBL20764034 0.77 ESRRG (0.70) ESRRGESR1ESR2HPGDSTP53
SCHEMBL23091201 0.76 HPGDS (0.72) ESRRGESR1ESR2HPGDSHSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795162-B2 Modulators of the estrogen-related receptor SAINT LOUIS UNIVERSITY (US) 2023-10-24 US disclosed
US-20200247792-A1 ERR INVERSE AGONISTS SAINT LOUIS UNIVERSITY (US) 2020-08-06 US disclosed
WO-2019036562-A1 ERR INVERSE AGONISTS SAINT LOUIS UNIVERSITY (US) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247792-A1 ERR INVERSE AGONISTS ESRRA, ESRRB, ESR2 ESRRG 4/4885ESR1 6/4885ESR2 3/4885
US-11795162-B2 Modulators of the estrogen-related receptor ESR2, GPER1, ESRRG ESRRG 3/4885ESR1 4/4885ESR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.